VEGFA and glioblastoma: However, recent phase III trials in newly-diagnosed GBM patients demonstrated a failure of the monoclonal anti-VEGF-directed antibody bevacizumab to extend overall survival when combined with chemotherapy and radiation therapy, despite benefits in progression-free survival and quality of life [40, 41].